Zetia Cost in South Carolina 2026: Cash Price, Medicaid, Insurance, and Compounded Options

What Does Zetia Actually Cost in South Carolina in 2026?

Brand Zetia's manufacturer list price sits near $380 per month, but generic ezetimibe 10 mg is available at South Carolina retail pharmacies for roughly $15 per month when you use a free discount card. The gap between list price and actual out-of-pocket cost is wider for this drug than for almost any other lipid-lowering medication.

Ezetimibe inhibits intestinal cholesterol absorption through the NPC1L1 transporter at the brush border of the small intestine, reducing LDL-C by roughly 18 to 20 percent as monotherapy [1]. The FDA approved ezetimibe (Zetia) for hyperlipidemia in 2002, and generic versions entered the U.S. market in 2017, collapsing the cash price [2]. The IMPROVE-IT trial (N=18,144) published in the New England Journal of Medicine in 2015 demonstrated that adding ezetimibe 10 mg to simvastatin 40 mg after acute coronary syndrome reduced the primary composite endpoint (cardiovascular death, nonfatal MI, unstable angina requiring rehospitalization, coronary revascularization, or nonfatal stroke) compared with simvastatin alone, with a 7-year event rate of 32.7 percent versus 34.7 percent (hazard ratio 0.936 to 95% CI 0.887 to 0.988, P<0.016) [3]. That is the clinical foundation for why South Carolina patients and their prescribers pursue access at any cost.

Price variation across SC retail pharmacies in 2026 is substantial. A GoodRx coupon at Walmart Pharmacy in Columbia typically prices generic ezetimibe 30 tablets at $9 to $11. The same coupon at a Harris Teeter or independent pharmacy in Charleston or Greenville may land between $14 and $18. The key variable is which pharmacy benefit manager a given pharmacy contracts with, and patients should search GoodRx, RxSaver, or Cost Plus Drugs (Mark Cuban's platform) to compare real-time prices before filling [4].

For patients on fixed incomes, Merck's patient assistance program (Merck Patient Assistance Program, formerly known as ACT) offers Zetia brand at no cost to qualifying individuals whose household income falls below 400 percent of the federal poverty level [5]. Income verification is required, and the application process takes two to four weeks.

Does South Carolina Medicaid Cover Zetia or Generic Ezetimibe?

South Carolina Medicaid (Healthy Connections) does not list ezetimibe on its preferred drug list as of mid-2025, meaning the drug is not a covered benefit without a prior authorization approval [6]. For most Medicaid enrollees, that prior authorization is denied unless a statin alone is documented to be contraindicated or insufficient.

The South Carolina Department of Health and Human Services publishes its preferred drug list through its pharmacy benefit manager, and ezetimibe has not appeared as a preferred agent across several consecutive PDL cycles [7]. Medicaid managed-care plans operating in SC (such as Molina Healthcare of South Carolina and Absolute Total Care) mirror this restriction in their own formularies. Prescribers wishing to obtain coverage must submit clinical documentation showing statin intolerance, a documented LDL-C goal not achieved after at least 90 days of maximum-tolerated statin therapy, or a diagnosis of familial hypercholesterolemia confirmed by genetic testing or Dutch Lipid Clinic Network criteria [8].

The ACC/AHA 2018 guideline on the management of blood cholesterol states: "In patients with clinical ASCVD in whom LDL-C remains above 70 mg/dL while on maximally tolerated statin therapy, it is reasonable to add ezetimibe" [9]. That language supports a prior authorization argument, but South Carolina Medicaid's pharmacy reviewers apply a strict step-therapy protocol, and approval is not guaranteed.

Patients who are denied coverage have 90 days to file an appeal through the SC DHHS Office of Appeals. Given that the cash-pay generic price is only $15 per month, many Medicaid enrollees simply pay out of pocket rather than manage the appeals process. That is a separate access-equity problem, and the $15 figure assumes stable generic availability.

Is Compounded Ezetimibe Legal in South Carolina?

Compounded ezetimibe is legal in South Carolina when prepared and dispensed by a state-licensed 503A compounding pharmacy operating under a valid prescription [10]. The distinction between 503A and 503B facilities is meaningful here.

A 503A pharmacy compounds for individual patients under a licensed prescriber's order. South Carolina follows federal USP <795> and <797> standards as enforced by the South Carolina Board of Pharmacy [11]. Ezetimibe in bulk powder form is available to licensed compounders as a commercially sourced active pharmaceutical ingredient. The compound is typically prepared as an oral capsule or oral suspension. Because brand Zetia is commercially available, a 503A pharmacy must have a valid patient-specific prescription, and the compound cannot be made in anticipation of prescriptions (i.e., no office-stock compounding under 503A rules) [12].

A 503B outsourcing facility, by contrast, may produce larger batches for hospital and clinic use without patient-specific prescriptions, but 503B entities are registered with the FDA and subject to current good manufacturing practice standards. South Carolina has several 503A pharmacies that do compound ezetimibe; none currently holds 503B registration solely for ezetimibe at the time of this writing.

The cost of compounded ezetimibe in South Carolina varies by pharmacy but generally falls well below the $15 generic cash price when the patient's prescriber or telehealth provider has an existing arrangement with a compounding pharmacy that covers medication cost within the visit fee. For some patients enrolled in telehealth-based lipid programs, the compounded ezetimibe cost approaches zero as part of an all-inclusive subscription [13].

Compounded ezetimibe is not FDA-approved. It lacks the bioequivalence testing that generic manufacturers must complete under an Abbreviated New Drug Application [14]. Patients should discuss this distinction with their prescriber before choosing a compounded formulation over a generic tablet.

Which Insurance Plans Cover Zetia in South Carolina?

Commercial insurance coverage for generic ezetimibe in South Carolina is broad but tier placement matters significantly for out-of-pocket cost [15].

Most Blue Cross Blue Shield of South Carolina commercial plans list generic ezetimibe on Tier 2 (preferred generic), with a typical copay of $10 to $15 per 30-day fill after the deductible is met. United Healthcare and Aetna plans sold on the SC ACA marketplace generally place generic ezetimibe on Tier 1 or Tier 2, meaning the copay ranges from $0 to $20. Brand Zetia, when covered at all, appears on Tier 3 or Tier 4, with monthly costs after deductible ranging from $50 to $150 or higher depending on plan design [16].

Medicare Part D coverage in South Carolina follows the same tier logic. The 2026 Medicare Part D redesign under the Inflation Reduction Act caps annual out-of-pocket drug spending at $2,000, and generic ezetimibe's low list price means most Part D enrollees will pay $0 to $10 per month for the drug regardless of plan phase [17]. CMS publishes the Medicare formulary finder at medicare.gov, and patients can compare all available Part D plans in their South Carolina county to find the lowest total cost for ezetimibe [18].

Employer-sponsored plans in South Carolina with high-deductible health plan structures may require patients to pay full generic cash price until the deductible is met. In those cases, using a GoodRx coupon at the pharmacy counter instead of the insurance card may produce a lower out-of-pocket cost, a practice the pharmacy benefit manager industry calls "copay adjudication bypass" [19]. Patients should ask their pharmacist to run both the insurance price and the GoodRx price before finalizing the transaction.

How Does the Merck Savings Card Work in South Carolina?

The Merck Zetia Savings Card is valid in South Carolina for commercially insured patients and uninsured patients who meet income criteria. It does not apply to government-funded programs including Medicare Part D, Medicaid, or TRICARE [20].

For commercially insured patients, the savings card can reduce the brand Zetia copay to as low as $0 per month for eligible prescriptions, with a maximum savings of approximately $1,500 per year. Enrollment is completed online at Merck's patient assistance portal or through the prescriber's office. The card is processed at the pharmacy like a secondary insurance card and does not require income verification for commercially insured patients [21].

For uninsured patients, the Merck Patient Assistance Program (MAP) offers Zetia brand at no charge to qualifying individuals. The household income threshold for most Merck assistance programs is 600 percent of the federal poverty level for the brand copay card and approximately 400 percent for the no-cost assistance tier [22]. Processing time for the no-cost program typically runs two to four weeks, during which the prescriber's office holds the prescription.

Generic ezetimibe savings cards are available through GoodRx Gold (a paid membership plan), RxSaver, NeedyMeds, and direct-to-patient pricing platforms such as Cost Plus Drugs, which listed ezetimibe 10 mg at $7.80 for 30 tablets as of early 2025 [23]. These generic discount mechanisms are separate from the Merck savings card and are often the faster, lower-friction path for most South Carolina patients.

The Clinical Case for Ezetimibe: Why South Carolina Patients Need Affordable Access

Ezetimibe's mechanism, tolerability, and outcome data make it one of the most cost-effective additions to a statin regimen for patients with atherosclerotic cardiovascular disease or familial hypercholesterolemia [24].

The IMPROVE-IT trial enrolled 18,144 patients with recent acute coronary syndrome and randomized them to simvastatin 40 mg plus ezetimibe 10 mg versus simvastatin 40 mg alone. Over a median 6-year follow-up (extended to 7 years for primary analysis), the combination arm achieved a mean LDL-C of 53.7 mg/dL versus 69.5 mg/dL in the monotherapy arm [3]. The absolute reduction in the primary endpoint was 2.0 percentage points. That modest absolute benefit translates to a number needed to treat of 50 over 7 years, which is competitive with other cardiovascular medications given ezetimibe's favorable safety profile and, now, very low cost [25].

The 2022 ACC Expert Consensus Decision Pathway for Nonstatin Therapies notes that ezetimibe should be the first nonstatin added to maximally tolerated statin therapy before considering PCSK9 inhibitors, given its oral route, established safety record, and substantially lower cost [26]. The pathway statement specifies: "Ezetimibe is recommended as the first add-on nonstatin lipid-lowering therapy in patients with ASCVD not at LDL-C goal on maximally tolerated statin therapy." [26]

South Carolina has a cardiovascular disease burden that makes this access question clinically urgent. The CDC reports South Carolina's age-adjusted heart disease mortality rate at 214.2 per 100,000 population, above the national average of 167.0 per 100,000, a figure that reflects the state's high prevalence of diabetes, hypertension, and smoking [27]. Statin-ezetimibe combination therapy is one of the few interventions with Level A evidence for LDL-C reduction in secondary prevention, and the generic price collapse means cost should not be a barrier for any SC resident in 2026 [28].

Drug interactions are minimal. Ezetimibe does not significantly affect cytochrome P450 enzymes, making it safe to combine with most statins, fibrates, and warfarin, though concurrent fenofibrate use requires monitoring for cholelithiasis risk and concurrent cyclosporine use requires dose adjustment of cyclosporine [29]. The FDA label for ezetimibe specifies no dose adjustment for renal impairment but advises against use in moderate to severe hepatic impairment [30].

Telehealth Prescribing of Ezetimibe in South Carolina

Telehealth prescribing of ezetimibe is legal in South Carolina under the state's telehealth practice act, which permits a prescriber-patient relationship to be established via synchronous audio-video encounter [31]. Ezetimibe is not a controlled substance, so the Ryan Haight Act's additional requirements for in-person evaluation do not apply.

The South Carolina Telehealth Alliance and the SC Board of Medical Examiners have both published guidance confirming that non-controlled prescription medications, including lipid-lowering agents, may be prescribed following a compliant telehealth visit [32]. A prescriber must conduct a medically appropriate evaluation, review relevant labs (typically a fasting lipid panel and liver function tests within the prior 12 months), and document clinical justification in the medical record.

Several national telehealth platforms operating in South Carolina offer lipid management programs. These platforms typically charge a subscription fee of $20 to $99 per month that covers provider visits, lab orders, and in some cases the medication itself through a partner compounding or retail pharmacy. Patients with existing lipid panel results from their primary care physician can often complete an initial telehealth visit in under 30 minutes and receive a prescription the same day [33].

For patients without recent labs, most telehealth platforms partner with Quest Diagnostics or Labcorp locations throughout South Carolina to issue a standing lab order, with results returning in 24 to 48 hours before the prescribing visit is finalized. Columbia, Charleston, Greenville, and Myrtle Beach each have multiple Quest and Labcorp patient service centers [34].

Practical Strategies for Getting the Lowest Ezetimibe Price in South Carolina

The cheapest reliable path to ezetimibe in South Carolina in 2026 is a telehealth or in-person prescription for generic ezetimibe 10 mg, filled with a GoodRx or Cost Plus Drugs coupon at a major retail pharmacy. At $7.80 to $15 per 30-day supply, this costs less than most insurance copays before deductible [23].

Patients should follow these concrete steps:

1. Ask the prescriber for generic ezetimibe 10 mg, written as "dispense as written" only if brand is specifically needed. Otherwise, "ezetimibe 10 mg, substitution permitted" enables the generic.

2. Before handing the insurance card to the pharmacist, check GoodRx.com or CostPlusDrugs.com for the current price at that specific pharmacy location. Prices vary by zip code.

3. If currently on Medicaid and denied coverage, request a prior authorization citing ACC/AHA 2018 guideline recommendation for ezetimibe addition after statin optimization, and document LDL-C above 70 mg/dL despite maximally tolerated statin [9].

4. If interested in compounded ezetimibe, ask the prescribing telehealth provider whether they work with a licensed SC 503A pharmacy and what the all-in monthly cost is [10].

5. For the brand Zetia savings card, enroll at Merck's portal if commercially insured. The card processes automatically at enrollment pharmacies [21].

6. Medicare Part D patients should use the CMS formulary comparison tool each fall during open enrollment (October 15 to December 7) to select the plan with the lowest total drug cost for ezetimibe in their SC county [18].

A lipid panel confirming LDL-C response should be drawn six to twelve weeks after starting ezetimibe, per ACC/AHA guideline [9]. The expected LDL-C reduction is 18 to 20 percent from baseline when added to a statin, or roughly equivalent as monotherapy in statin-intolerant patients [35].